HiberCell

Targeting the Integrated Stress Response in Cancer

New York, United States · Founded 2019 · $67.4M raised

Headquarters
New York
Employees
51–200
Founded
2019
Business Model
B2B
Total Funding
$67.4M
Last Round
$67.4M Series BMay 2021
Rounds
1

About

HiberCell is a clinical-stage oncology company developing first-in-class treatments that modulate adaptive stress pathways and anti-tumor immunity. Its programs address mechanisms associated with treatment resistance, relapse, and metastasis. The company’s clinical candidates include HC-7366, a GCN2 activator, and HC-5404, a PERK inhibitor, which target stress-response pathways in cancer cells. HiberCell is advancing these candidates to help patients live longer, cancer-free lives.

Summary

HiberCell is a Biotech company based in New York, United States, founded in 2019. It has raised $67.4M in total across 1 round, most recently a $67.4M Series B round in May 2021. Investors include Hercules Capital, Huizenga Capital Management and Monashee Capital Inc..

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Debt FinancingDebt FacilityMay 2021
$30.0M

Sign up to see all 2 rounds

Debt Financing through Series B — per-round amounts, valuations, and who invested in each round.

Investors

Acquisitions

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

HiberCell on Indexed.vc
<a href="https://indexed.vc/companies/hibercell"><img src="https://indexed.vc/api/badge/company/hibercell" alt="HiberCell on Indexed.vc" width="260" height="76" /></a>